UniCure: A multi-modal model for predicting personalized cancer therapy response
Cancer Cell · 2026
DOI: 10.1016/j.ccell.2026.07.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2026. Verfasst von Zexi Chen und 22 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Cell Biology, Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese A…. Hauptthemen laut MEDLINE: Precision Medicine, Neoplasms, Antineoplastic Agents, Models, Biological. Die Arbeit nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key Technologies Research and Development Program.
Abstract (Originalsprache)
Predicting drug efficacy across diverse patient contexts remains a major challenge in oncology, as models trained on cancer cell lines often fail to capture patient-specific biology. Emerging biological foundation models and patient-derived technologies offer a promising solution. Here, we present UniCure, a multi-modal model that combines biological and chemical foundation models to predict drug-induced transcriptomic responses across diverse cell and tissue contexts, enabling individualized drug ranking. Trained on 1.9 million transcriptomic perturbation profiles spanning >22,000 compounds, 166 cell types, and 24 tissues, UniCure accurately predicts dose-dependent and combination responses and generalizes across bulk and single-cell data. We further fine-tune UniCure on 345 patient-derived tumor-like cluster (PTC) transcriptomic profiles and validate performance on 396 real-world clinical profiles, demonstrating effective patient-level prediction. The model supports response-based patient stratification and is experimentally validated in cell line and patient-derived models. Overall, UniCure provides a practical framework for translating preclinical data into personalized therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Cell Biology, Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai 200031, China; Department of Medical Onco…
- Department of Phytochemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China. Electronic address: saisai_tian@foxmail.com.
- State Key Laboratory of Cell Biology, Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai 200031, China; University of Chinese Acad…
- DP Technology, Beijing, China.
- Breast Center, Peking University People's Hospital, Beijing 100044, China.
- Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- Key Technologies Research and Development Program
Zitieren
APA
Chen, Z., Tian, S., Pei, J., Gu, R., Li, Y., Ding, S., Xu, Y., Zheng, X., Liu, M., Du, X., Zhou, Y., Zhu, J., Zou, J., Xu, J., Jiang, W., Ye, C., Dong, B., Zhang, Q., Ren, S., …, & Chen, L. (2026). UniCure: A multi-modal model for predicting personalized cancer therapy response. Cancer Cell. https://doi.org/10.1016/j.ccell.2026.07.010
Vancouver
Chen Z, Tian S, Pei J, Gu R, Li Y, Ding S, et al. UniCure: A multi-modal model for predicting personalized cancer therapy response. Cancer Cell. 2026. doi:10.1016/j.ccell.2026.07.010
BibTeX
@article{Chen2026,
author = {Chen, Zexi and Tian, Saisai and Pei, Jiazheng and Gu, Ruichu and Li, Yongge and Ding, Shizhi and Xu, Yaqian and Zheng, Xinlong and Liu, Miaoyu and Du, Xinxing and Zhou, Yuanyuan and Zhu, Junchao and Zou, Jiawei and Xu, Jing and Jiang, Wenli and Ye, Chen and Dong, Baijun and Zhang, Qi and Ren, Shengxiang and Wang, Shu and Wen, Han and Zhang, Weidong and Chen, Luonan},
title = {UniCure: A multi-modal model for predicting personalized cancer therapy response},
journal = {Cancer Cell},
year = {2026},
doi = {10.1016/j.ccell.2026.07.010}
}
EUVIMED